Antibiotics

Antibiotics
Mupirocin [HOT]
4-AA [Intermediate] [HOT]

 

 

Antibiotics
6.8kg Mupirocin,USP37;3.2kg Mupirocin Ca,EP;0.3MT Amikacin sulfate USP37 are in-stock
12650-69-0
USP37
Mupirocin [HOT]
Appearance
White to Off-white powder
Identification
Positive
pH(25℃)
3.5-4.5
Crystallinity
Meet the requirement
Water
Not more than 1.0%
Assay(Dried basis)
92.0%-102.0%
Residual solvents
Ethyl acetate:Not more than 500ppm
Isobutyl acetate:Not more than 5000ppm
Heptane:Not more than 500ppm
Acetone:Not more than 500ppm
115074-43-6
EPVII
73346-79-9
>95%
1405-87-4
>95%
1405-89-6
>99%
149022-22-0
USP37
29676-71-9
>99%
4-AA [Intermediate]
76855-69-1
99%
1405-20-5
USP35
81103-11-9
USP37/EPVII
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(s).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.